The same group reported that enarodustat also exerted renoprotective effects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice by improving glucose and lipid metabolism and suppression of CCL2/MCP-1 (Sugahara et al., 2020) (Figure 1). Here, CCL2 is linked to Other metabolic disease.